The qualitative omission is not: neither projection addresses the validation infrastructure required for clinical deployment.
A peer-reviewed framework published in Nature on September 3 addresses that omission in structural terms. Titled "A five-phase evaluation framework for diagnostic and predictive medical artificial intelligence," the publication defines sequenced evaluation criteria for medical AI systems.
The Commercial-Regulatory Divergence
Capital markets price AI pharmacovigilance platforms on projected revenue. Regulatory authorities price them on demonstrated efficacy. The divergence between these two mechanisms defines the deployment risk for any safety operation considering procurement.
The 20.2% CAGR figure originates from an analysis distributed via EIN News. The 19.6% figure originates from a separate projection distributed via EIN Presswire. Both are forecasts. Neither constitutes a validation certificate.
The Nature framework introduces phase-gated evaluation. Five discrete phases replace continuous deployment with sequential accountability. Each phase establishes a determinate threshold. Systems failing at any phase are excluded from downstream progression.
For pharmacovigilance operations, the implications extend directly across signal detection, causality assessment, and automated case processing. Variance in AI performance within these domains translates into measurable variance in post-market safety outcomes.
Required Procurement Documentation
Operations evaluating AI platform acquisition should require from prospective vendors:
1. Documented completion status for each of the five evaluation phases, with version-controlled evidence.
2. Quantifiable performance metrics specific to pharmacovigilance use cases, distinct from generalized benchmark scores.
3. Regulatory submission history demonstrating prior agency review at any jurisdiction.
4. Third-party validation documentation independent of vendor self-assessment.
Vendor marketing collateral does not constitute phase-gate evidence.
Risk Posture
Procurement decisions driven exclusively by commercial growth projections, absent phase-gate validation, introduce unquantified variance into drug safety infrastructure. The mitigation cost accrues to patient safety. It does not accrue to the vendor balance sheet.